That's a pretty big change in a pretty short time, roughly half as much time as the semaglutide 7.2 mg study for half as much weight loss, and Novo Nordisk says it is "very encouraged" by this ...
Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...
Novo Nordisk hopes the new treatment can build on the success of its flagship obesity drug, Wegovy. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this ...
Novo Nordisk said the Food and Drug Administration ... of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday.
Novo’s stock fell slightly in early December after a trial sponsored by Lilly found that patients who took Zepbound lost 20.2% of their body weight, on average, compared with just a 13.7% ...
Roughly 40% of Type 2 diabetes patients have the condition, which can cause additional sickness such as increased risk of cardiovascular problems and death, Novo Nordisk said. "All chronic kidney ...
Internet sleuths have theorized the screen will be 7.5 inches (a big jump from the Switch’s 6.2-inch display). Another noticeable design tweak is the new kickstand. It will cover the entire back ...
The Toronto Blue Jays clearly don't want to trade first baseman Vladimir Guerrero Jr., but if they do, the New York Mets might be the most likely destination. Unless Pete Alonso and the Mets can ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback